The Wisconsin Alumni Research Foundation granted FluGen rights for the development of antiviral drugs that can stop viruses several days after the manifestation of flu symptoms. The class of compounds, which use a peptide to keep the influenza virus out of human cells, could enter clinical trials in 12 to 18 months, the biotech firm said.

Related Summaries